IgM and IgD in Infection and Inflammatory Diseases

Karlsson, Mikael C. I.

doi:10.1007/978-1-4614-7107-3_1

Cited by 1 publication

(1 citation statement)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunoglobulin M (IgM) is the largest antibody in serum and its level is elevated in various inflammatory and autoimmune diseases ( 276 ). It is another highly N-glycosylated antibody, as its constant domain contains five N-linked glycosylation sites, three of which belong to the biantennary complex form (Asn171, Asn332, Asn395) and two to the oligomannose type (at Asn402, Asn563) ( 219 ).…”

Section: Adaptive Immunitymentioning

confidence: 99%

N-Glycosylation and Inflammation; the Not-So-Sweet Relation

Radovani

Gudelj²

2022

Front. Immunol.

View full text Add to dashboard Cite

Chronic inflammation is the main feature of many long-term inflammatory diseases such as autoimmune diseases, metabolic disorders, and cancer. There is a growing number of studies in which alterations of N-glycosylation have been observed in many pathophysiological conditions, yet studies of the underlying mechanisms that precede N-glycome changes are still sparse. Proinflammatory cytokines have been shown to alter the substrate synthesis pathways as well as the expression of glycosyltransferases required for the biosynthesis of N-glycans. The resulting N-glycosylation changes can further contribute to disease pathogenesis through modulation of various aspects of immune cell processes, including those relevant to pathogen recognition and fine-tuning the inflammatory response. This review summarizes our current knowledge of inflammation-induced N-glycosylation changes, with a particular focus on specific subsets of immune cells of innate and adaptive immunity and how these changes affect their effector functions, cell interactions, and signal transduction.

show abstract

Section: Adaptive Immunitymentioning

confidence: 99%